CAS: 66-76-2; Dicoumarol

上下游产品

maleic anhydride 3-(NN-dimethylaminomethyl)-4-hydroxycoumarin methanol 4-hydroxy[1]benzopyran-2-oneH-chromen-3-yl)-methanebis-(2-oxo-4-pivaloyloxy-2H-chromen-3-yl)-methane H-chromen-3-yl)-methanebis-(4-benzoyloxy-2-oxo-2H-chromen-3-yl)-methane 4-hydroxy-3-[3-(2-hydroxyphenyl)-3-oxopropyl]-2H-chromen-2-one H-chromen-3-yl)-methanebis-(4-acetoxy-2-oxo-2H-chromen-3-yl)-methane

📜4-羟基香豆素置于盐酸,三氯氧磷体系中,用 乙醇,二甲基亚砜 作为反应溶剂,化学反应 5.5H,反应生成 双香豆素
参考文献:Synthesis And Study Of The Properties Of 4-Substituted 3-Aminomethylcoumarins
标题:Synthesis And Study Of The Properties Of 4-Substituted 3-Aminomethylcoumarins
摘要:
DOI:10.1007/bf00568940

专利信息

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:WO-2015194928-A1
优先权日:2014-06-17
标 题:Method for the isolation and synthesis of 3-(1´, 1´- dimethylallyl)-herniarin, as well as (e)-3-(1´,1´-dimethyl-3´nitro-allyl-herniarin, from casimiroa pubescens, and use thereof as an antidepressant
发明人：MARTÃ?NEZ VÃ?ZQUEZ MARIANO; ESTRADA REYES ROSA; UBALDO SUÃ?REZ DENISSE; DE LA ROSA SIERRA ROBERTO
权利人:UNIV NAC AUTÓNOMA DE MÉXICO
摘要:The invention relates to the compounds 3-(1´,1´ -dimethylallyl)-herniarin (1) y 3- (1,1´-dimethyl-3´ nitro allyl-herniarin] (3) (NHR) derived from coumarin, which have excellent antidepressant activity. The compound 3- (1,1´-dimethyl-3´ nitro allyl-herniarin] (3) (NHR) is synthesised by means of a nitration reaction of the compound 3-(1´,1´-dimethylallyl)-herniarin. The present invention also relates to the method for the isolation and synthesis of the compound 3 -(1´,1´-dimethylallyl)-herniarin.

专利号:US-2003050305-A1
优先权日:2000-05-22
标题:Thromboxane inhibitors, compositions and methods of use
发明人：TEJADA INIGO SAENZ DE
摘要:The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.

专利号:WO-02061120-A1
优先权日:2001-02-01
标题:Method of evaluating ability of drug to induce enzyme in liver cells
发明人：OHTA KUNIHIRO; NAKAGAWA TOSHITO
权利人:CHUGAI PHARMACEUTICAL CO LTD; OHTA KUNIHIRO; NAKAGAWA TOSHITO
摘要:A method of evaluating the ability of a test drug to induce the synthesis of CYP (cytochrome P450) in liver cells characterized by comprising culturing the liver cells in a culture medium containing the test drug in the presence of matrigel and evaluating the ability of the test drug to induce the synthesis of CYP by assaying the enzymatic activity of CYP in the culture medium.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-6869973-B2
优先权日:2000-06-22
标题:Nitrosated and nitrosylated taxanes, compositions and methods of use
发明人：GARVEY DAVID S; LETTS L GORDON; LIN CHIA-EN; RICHARDSON STEWART K; WANG TIANSHENG
权利人:NITROMED INC
摘要:The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.